AU2001231763A1 - Dosing regimen - Google Patents
Dosing regimenInfo
- Publication number
- AU2001231763A1 AU2001231763A1 AU2001231763A AU3176301A AU2001231763A1 AU 2001231763 A1 AU2001231763 A1 AU 2001231763A1 AU 2001231763 A AU2001231763 A AU 2001231763A AU 3176301 A AU3176301 A AU 3176301A AU 2001231763 A1 AU2001231763 A1 AU 2001231763A1
- Authority
- AU
- Australia
- Prior art keywords
- dosing regimen
- abbreviated
- treatment
- relates
- transferase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
This invention relates to a method of treatment and dosing regimen for treating mammalian tumors by the discontinuous administration of a farnesyl transferase inhibitor over an abbreviated one to five day dosing schedule.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18455100P | 2000-02-24 | 2000-02-24 | |
US60184551 | 2000-02-24 | ||
PCT/EP2001/001937 WO2001062234A2 (en) | 2000-02-24 | 2001-02-20 | Dosing regimen |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001231763A1 true AU2001231763A1 (en) | 2001-09-03 |
Family
ID=22677368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001231763A Abandoned AU2001231763A1 (en) | 2000-02-24 | 2001-02-20 | Dosing regimen |
Country Status (9)
Country | Link |
---|---|
US (1) | US6838467B2 (en) |
EP (1) | EP1267848B1 (en) |
JP (1) | JP2003523381A (en) |
AT (1) | ATE375794T1 (en) |
AU (1) | AU2001231763A1 (en) |
CA (1) | CA2397558A1 (en) |
DE (1) | DE60130976T2 (en) |
ES (1) | ES2293972T3 (en) |
WO (1) | WO2001062234A2 (en) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1255537E (en) * | 2000-02-04 | 2006-09-29 | Janssen Pharmaceutica Nv | FARNESIL PROTEIN INHIBITORS TRANSFERASE TO TREAT BREAST CANCER |
JO2361B1 (en) * | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Farnesyl transferase inhibiting 1-2 annelated quinoline enantiomer |
WO2002064142A1 (en) * | 2001-02-15 | 2002-08-22 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with antiestrogen agents |
AU2002352941A1 (en) * | 2001-11-30 | 2003-06-17 | Schering Corporation | Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer |
CA2547518A1 (en) | 2003-12-12 | 2005-06-30 | Wyeth | Quinolines useful in treating cardiovascular disease |
AP2188A (en) * | 2004-01-23 | 2010-12-14 | Janssen Pharmaceutica Nv | Substituted quinolines and their use as mycobacterial inhibitors. |
WO2005089518A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Uch-l1 expression and cancer therapy |
US20050272722A1 (en) * | 2004-03-18 | 2005-12-08 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
CA2559282A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
EP1744751A4 (en) * | 2004-03-18 | 2010-03-10 | Brigham & Womens Hospital | Methods for the treatment of synucleinopathies |
US20060106060A1 (en) * | 2004-03-18 | 2006-05-18 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
US20060194821A1 (en) * | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
WO2007075923A2 (en) | 2005-12-23 | 2007-07-05 | Link Medicine Corporation | Treatment of synucleinopathies |
MX2009004554A (en) * | 2006-10-25 | 2009-05-11 | Schering Corp | Discontinuous methods of treating cancer. |
WO2009151683A2 (en) * | 2008-03-12 | 2009-12-17 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
US9561214B2 (en) * | 2008-10-16 | 2017-02-07 | Array Biopharma Inc. | Method of treatment using inhibitors of mitosis |
BRPI0920927A2 (en) * | 2008-11-13 | 2019-09-24 | Link Medicine Corp | azaquinolinone derivatives and uses thereof |
US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
US9303015B2 (en) | 2012-10-16 | 2016-04-05 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORγt |
ES2628365T3 (en) | 2012-10-16 | 2017-08-02 | Janssen Pharmaceutica N.V. | Phenyl-linked quinolinyl modulators of ROR-GAMA-T |
MX358508B (en) | 2012-10-16 | 2018-08-22 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of ror-gamma-t. |
US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
CA2927182A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | Quinolinyl modulators of ror.gamma.t |
US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
EP3057421B1 (en) | 2013-10-15 | 2019-11-20 | Janssen Pharmaceutica NV | Alkyl linked quinolinyl modulators of ror(gamma)t |
US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
KR102514971B1 (en) | 2015-04-21 | 2023-03-27 | 아이거 바이오파마슈티컬스 인코포레이티드 | Pharmaceutical composition comprising lonafarnib and ritonavir |
SG10202101740QA (en) | 2015-08-17 | 2021-04-29 | Kura Oncology Inc | Methods of treating cancer patients with farnesyl transferase inhibitors |
US20190119758A1 (en) | 2016-04-22 | 2019-04-25 | Kura Oncology, Inc. | Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors |
JP2019534290A (en) | 2016-11-03 | 2019-11-28 | クラ オンコロジー, インコーポレイテッド | Farnesyltransferase inhibitors for use in methods of treating cancer |
EP3432883B1 (en) | 2017-02-21 | 2021-07-28 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
US10137121B2 (en) | 2017-02-21 | 2018-11-27 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
MY200746A (en) | 2017-08-07 | 2024-01-13 | Kura Oncology Inc | Methods of treating cancer with farnesyltransferase inhibitors |
US10806730B2 (en) | 2017-08-07 | 2020-10-20 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
WO2019113269A1 (en) | 2017-12-08 | 2019-06-13 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
CA3117968A1 (en) | 2018-11-01 | 2020-05-07 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
SG11202106599WA (en) | 2018-12-21 | 2021-07-29 | Kura Oncology Inc | Therapies for squamous cell carcinomas |
US20220142983A1 (en) | 2019-03-01 | 2022-05-12 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
TW202108170A (en) | 2019-03-15 | 2021-03-01 | 美商庫拉腫瘤技術股份有限公司 | Methods of treating cancer patients with farnesyltransferase inhibitors |
SG11202110472WA (en) | 2019-03-29 | 2021-10-28 | Kura Oncology Inc | Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors |
TW202102218A (en) | 2019-04-01 | 2021-01-16 | 美商庫拉腫瘤技術股份有限公司 | Methods of treating cancer with farnesyltransferase inhibitors |
WO2020223583A1 (en) | 2019-05-02 | 2020-11-05 | Kura Oncology, Inc. | Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5686472A (en) | 1992-10-29 | 1997-11-11 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5834434A (en) * | 1993-05-18 | 1998-11-10 | University Of Pittsburgh | Inhibitors of farnesyltransferase |
TW349948B (en) | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
DE69620445T2 (en) * | 1995-12-08 | 2002-12-12 | Janssen Pharmaceutica Nv | (IMIDAZOL-5-YL) METHYL-2-CHINOLINO DERIVATIVES AS A FARNESYL PROTEIN TRANSFERASE INHIBITOR |
US5874442A (en) | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
DE69725604T2 (en) | 1996-12-20 | 2005-03-03 | Sergazy Mynzhasarovich Adekenov | METHOD AND APPARATUS FOR PREPARING VPM LYOPHILIZED 1β, 10β-EPOXY-13-DIMETHYLAMINO-GUAIA-3 (4) EN 6,12 OLID HYDROCHLORIDE |
TW591030B (en) | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
PL190944B1 (en) | 1997-04-25 | 2006-02-28 | Janssen Pharmaceutica Nv | A derivative of quinazolinone and method for its manufacture as well as pharmaceutical compound and method for its manufacture |
US6303654B1 (en) | 1998-03-12 | 2001-10-16 | Wisconsin Alumni Research Foundation | Acyclic monoterpenoid derivatives |
WO2000001691A1 (en) | 1998-07-01 | 2000-01-13 | Merck & Co., Inc. | Process for making farnesyl-protein transferase inhibitors |
NZ509372A (en) | 1998-08-27 | 2003-08-29 | Pfizer Prod Inc | Substituted quinolin-2-one derivatives, pharmaceuticals thereof and their use for treating abnormal cell growth (e.g. cancer) |
WO2000012498A1 (en) | 1998-08-27 | 2000-03-09 | Pfizer Products Inc. | Quinolin-2-one derivatives useful as anticancer agents |
DE69907964T2 (en) | 1998-12-23 | 2004-02-19 | Janssen Pharmaceutica N.V. | 1,2-FELLENED CHINOLINE DERIVATIVES |
-
2001
- 2001-02-20 DE DE60130976T patent/DE60130976T2/en not_active Expired - Lifetime
- 2001-02-20 US US10/220,162 patent/US6838467B2/en not_active Expired - Lifetime
- 2001-02-20 JP JP2001561301A patent/JP2003523381A/en not_active Withdrawn
- 2001-02-20 EP EP01903785A patent/EP1267848B1/en not_active Expired - Lifetime
- 2001-02-20 AU AU2001231763A patent/AU2001231763A1/en not_active Abandoned
- 2001-02-20 AT AT01903785T patent/ATE375794T1/en active
- 2001-02-20 CA CA002397558A patent/CA2397558A1/en not_active Abandoned
- 2001-02-20 WO PCT/EP2001/001937 patent/WO2001062234A2/en active IP Right Grant
- 2001-02-20 ES ES01903785T patent/ES2293972T3/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US6838467B2 (en) | 2005-01-04 |
EP1267848B1 (en) | 2007-10-17 |
ES2293972T3 (en) | 2008-04-01 |
EP1267848A1 (en) | 2003-01-02 |
ATE375794T1 (en) | 2007-11-15 |
WO2001062234A2 (en) | 2001-08-30 |
DE60130976D1 (en) | 2007-11-29 |
CA2397558A1 (en) | 2001-08-30 |
DE60130976T2 (en) | 2008-07-17 |
JP2003523381A (en) | 2003-08-05 |
WO2001062234A8 (en) | 2001-09-27 |
US20030060450A1 (en) | 2003-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001231763A1 (en) | Dosing regimen | |
MY169308A (en) | Treatment of tnf? related disorders | |
HK1052708A1 (en) | Glutamine-thiazolidide and-pyrrolidide and their use as depeptidylpeptidase iv inhibitors. | |
MY150740A (en) | Low dose methods for treating disorders in which tnf? activity is detrimental | |
HK1156515A1 (en) | Pharmaceutical compositions and methods for accelerating wound healing | |
NZ515567A (en) | Method for treating chronic pain using MEK inhibitors | |
PL375900A1 (en) | Dosage forms containing a proton pump inhibitor, a nsaid, and a buffer | |
WO2003073999A3 (en) | Pini-modulating compounds and methods of use thereof | |
AU7321598A (en) | Use of cholinesterase inhibitors to treat disorders of attention | |
DK0915898T3 (en) | Crystal form I of clarithromycin | |
WO2003074550A3 (en) | Pin1-modulating compounds and methods of use thereof | |
AU2001233726A1 (en) | Farnesyl protein transferase inhibitors for treating breast cancer | |
WO2003101444A8 (en) | Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer | |
AU3451797A (en) | Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter | |
DE69725860D1 (en) | PLAN FOR ADMINISTRATION OF H +, K + -ATPase INHIBITORS | |
AU2001260880A1 (en) | Pharmaceutical compounds for treating copd | |
TW200508233A (en) | Chk-1 inhibitors | |
GB9907571D0 (en) | Compounds | |
AP9801261A0 (en) | Farnesyl transferase inhibitors in combination with HMG COA reductase inhibitors for the treatment of cancer. | |
AU2003274565A8 (en) | Composition for the treatment of nasopharyngeal carcinoma and method of use thereof | |
AU2576901A (en) | Agents and methods for the treatment of proliferative diseases | |
HUP0300576A2 (en) | Divided dose therapies with vascular damaging activity | |
ATE270113T1 (en) | COMPOSITIONS FOR IMPROVED WOUND HEALING | |
MXPA03006359A (en) | Method for treating cancer having greater efficacy and reduced adverse effects. | |
AU2629500A (en) | A method for treating patients with acne by administering a cyclic gmp pde inhibitor |